2020 ttf egfr breakout piotrowska part 2 - current options upon acquired resistance to osimertinib
Published 3 years ago • 155 plays • Length 18:44Download video MP4
Download video MP3
Similar videos
-
11:23
2020 ttf egfr breakout piotrowska part 1 - current options upon acquired resistance to osimertinib
-
2:06
2020 ttf egfr qa panel updates combo treatment of osimertinib (tagrisso) & ramucirumab (cyramza)
-
16:48
2020 ttf egfr breakout - weiss choice of frontline egfr therapies
-
7:09
2020 ttf egfr session - qa panel preferred chemo regimen when targeted therapy options are exhausted
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
1:39
2020 ttf egfr session qa panel what is the difference between c797s and c797x
-
19:31
2020 ttf am session - janne - insights into acquired resistance: the role of repeat biopsies
-
1:28
2020 ttf egfr qa panel can a tissue biopsy play a role in disrupting the cancer and cause spread
-
1:22:21
egfr breakout video targeted therapies 2017
-
2:10
slcvl raez #17 treatment options for acquired resistance to egfr tkis: t790m-negative disease
-
26:27
novel egfr inhibitors in the setting of acquired resistance
-
2:43
post-osimertinib treatment options for egfr nsclc - targeted therapies in lung cancer 2023
-
1:17:52
egfr initial treatment, acquired resistance and q&a with h. jack west, md and helena yu, md
-
28:22
gracecast-088_lung-cancer_challenging cases in lung cancer: acquired resistance to egfr tki therapy
-
3:07
third generation egfr tkis for acquired resistance
-
2:21
should egfr tki therapy be continued beyond progression?
-
3:41
testing methods to discover egfr exon-20 disease - lung cancer video library
-
3:35
grace targeted therapies lung cancer 2021 - current treatment options for egfr fusions e.g. rad 51
-
1:45
gracecastuc-034_lung_management strategies for acquired resistance to targeted therapies